We have announced our audited results for the 12 months to 31 May 2025.
Operational highlights
- Awarded £495k digital infrastructure contract with Queen Victoria Hospital NHS Foundation Trust (“QVH”)
- Awarded further funding to extend the delivery of community diagnostic centre (“CDC”) pathway pilot at the Northern Care Alliance NHS Foundation Trust (“NCA”) site in Oldham
- Continued to progress discussions at a both a national level and locally with Integrated Care Boards (“ICBs”)
- Focus on waitlist rationalisation within the NHS provides compelling backdrop
- Feedback’s solutions tailored to the broader changing landscape
- MOU signed with primary care solutions partner and NHS Trust providing significant opportunities linked to the government’s Neighbourhood Health model
- Received HSJ Partnership Award for reducing patient wait times and unnecessary hospital appointments through a digital breathlessness pathway
- Commenced integration of Bleepa® with key NHS referral systems to provide greater scalability
- Broadened product functionality and reach via collaboration with Vertex In Healthcare (“Vertex”)
Financial highlights
- Revenue of £0.89m (2024: £1.18m)
- Sales1 were £0.89m (2024: £0.95m); Bleepa contributed 90%
- EBITDA loss of £3.06m (2024: £2.73m)
- Raised gross proceeds of approximately £6.1 million via a Placing and Retail Offer and completed a share capital reorganisation in November 2024
- Cash as at 31 May 2025 was £5.95m (31 May 2024: £3.88m)
- Sufficient for runway to early CY2027
“We have positioned the company and our technology base to provide digital solutions that will enable increased efficiency at the same time as reducing the huge burden on the NHS. It is clear that the Government is focused on addressing the numerous, well publicised issues facing our health system. We have the relationships and systems in place to scale up rapidly once the NHS 10-year plan and Spending Review are complete. It’s clear that the delays we have seen due to the ongoing changes to government and NHS funding programmes have impacted our performance during the period, however we remain well positioned to generate strong returns.”
Dr Tom Oakley, CEO of Feedback
You can read our full results for the 12 months ended May 2025 here.